Early Health Technology Assessment (HTA) of Olpasiran and Pelacarsen for Secondary Prevention of Coronary Heart Disease (CHD)

Elena Filipova,1,* Ivona Danova,1,* Iana Simova,2– 5,* Toni Vekov2,3,* 1Science Department, Tchaikapharma High Quality Medicines Ltd., Sofia, Bulgaria; 2Cardiology Department, Heart and Brain Center of Excellence, Pleven, Bulgaria; 3Bulgarian Cardiac Institute, Sofia,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Filipova E, Danova I, Simova I, Vekov T
Format:	Artigo
Idioma:	Inglês
Publicat:	Dove Medical Press 2026-04-01
Col·lecció:	ClinicoEconomics and Outcomes Research
Matèries:	lipoprotein(a) olpasiran pelacarsen cardiovascular risk cost-effectiveness
Accés en línia:	https://www.dovepress.com/early-health-technology-assessment-hta-of-olpasiran-and-pelacarsen-for-peer-reviewed-fulltext-article-CEOR
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!